IQVIA
Search results
ICON is the world's leading clinical research organisation, providing outsourced clincal development and commercialisation services to the pharmaceutical, biotechnology and medical device industries.
ICON has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards. Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
ICON plc is an Irish headquartered Nasdaq listed multinational healthcare intelligence and clinical research organisation that provides consulting, clinical development and commercialisation services for the pharmaceutical industry. [2]
Jul 19, 2024 · Streamlining early phase clinical trial submissions under the EU CTR. The EU Clinical Trials Regulation (CTR) represented a significant shift in the regulatory landscape, aiming to create a more favourable environment for clinical research across Europe. ICON has adeptly adapted to these new regulations, leveraging our Netherlands efficiencies ...
Jul 24, 2024 · ICON Reports Second Quarter 2024 Results. July 24, 2024. PDF Version. Highlights. Net business wins in the quarter of $2,579 million, an increase of 6.6% on quarter two 2023. Reflects a net book to bill in the quarter of 1.22, and a trailing twelve month net book to bill of 1.24.
Jul 24, 2024 · ICON is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations.
We are a global provider of consulting, and outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost and increasing quality – and our ...
Dublin, Ireland, 1st July 2021 – ICON plc, (NASDAQ: ICLR) today announced the completion of its acquisition of PRA Health Sciences. The combined company will retain the name ICON and will bring together 38,000 employees across 47 countries, creating the world’s most advanced healthcare intelligence and clinical research organisation.
Jun 10, 2024 · DUBLIN --(BUSINESS WIRE)--Jul. 24, 2024-- ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 23, 2024 were duly passed by shareholders.
ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations.
